HSPA1A and neoplasm: Inhibitory targeting the inducible HSP70 appears to be a suitable approach in terms of anticancer therapy, as malignant cells are known to be more “addicted” to this form of the chaperone than normal cells (see Section 3.1 and [36,37,38]) and, therefore, the cytotoxic effects of such targeting may stronger be manifested in tumor cells, thus yielding the sought selectivity.